Ivan Kairatov stands at the forefront of biopharmaceutical innovation, bringing years of dedicated research in oncology to the challenge of treating refractory cancers. His recent collaborative work with international teams from the Netherlands, Italy, and Slovakia has shed new light on germ cell
We are joined by Ivan Kairatov, a biopharma expert with deep insights into the intricate world of drug research and development. In our conversation, we’ll explore the high-stakes landscape of regulatory approvals, touching on Bristol Myers Squibb's pivotal new cancer therapy, the challenging path
While traditional breast cancer screening saves lives, its methods often involve discomfort, radiation, and high costs, creating significant barriers for many. A new wave of technology is emerging to change that. Ultra-Low Field (ULF) MRI is gaining traction as a potential solution, promising a
The rapid ascent of GLP-1 agonists as a cornerstone therapy for diabetes and obesity has been nothing short of revolutionary, yet this widespread adoption brings into sharp focus the critical need to look beyond their celebrated benefits and scrutinize their full safety profile. As millions of
The persistent search for a long and healthy life has often prioritized cardiovascular fitness, yet a groundbreaking study suggests a more fundamental measure of vitality might be found in something as simple as the strength of your grip. This new body of research illuminates a powerful,
In the high-stakes world of pharmaceutical development, a successful Phase 3 trial is typically a cause for celebration, yet Ocular Therapeutix's recent announcement for its wet AMD treatment, Axpaxli, was met with a starkly different reality. The drug achieved its primary endpoint with statistical
